Litcius/Paper detail

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma

Samuel S. Freeman, Moshe Sade-Feldman, Jaegil Kim, Chip Stewart, Anna Gonye, Arvind Ravi, Monica Arniella, Irena Gushterova, Thomas J. LaSalle, Emily M. Blaum, Keren Yizhak, Dennie T. Frederick, Tatyana Sharova, Ignaty Leshchiner, Liudmila Elagina, Oliver Spiro, Dimitri Livitz, Daniel Rosebrock, François Aguet, Jian Carrot‐Zhang, Gavin Ha, Ziao Lin, Jonathan Chen, Michal Barzily-Rokni, Marc R. Hammond, Hans C. Vitzthum von Eckstaedt, Shauna Blackmon, Yunxin J. Jiao, Stacey Gabriel, Donald P. Lawrence, Lyn M. Duncan, Anat Stemmer‐Rachamimov, Jennifer A. Wargo, Keith T. Flaherty, Ryan J. Sullivan, Genevieve M. Boland, Matthew Meyerson, Gad Getz, Nir Hacohen

2022Cell Reports Medicine35 citationsDOIOpen Access PDF

Abstract

. Overall, RNA or DNA-based models combining immune and tumor measures improve predictions of melanoma CPB outcomes.

Topics & Concepts

Immune checkpointMelanomaTranscriptomeImmune systemExomeExome sequencingGeneCancer researchRNAImmunotherapyBlockadeT-cell receptorComputational biologyBiologyT cellMedicineImmunologyGene expressionGeneticsMutationReceptorCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsImmunotherapy and Immune Responses